CH652145A5 - Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. - Google Patents

Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. Download PDF

Info

Publication number
CH652145A5
CH652145A5 CH409/82A CH40982A CH652145A5 CH 652145 A5 CH652145 A5 CH 652145A5 CH 409/82 A CH409/82 A CH 409/82A CH 40982 A CH40982 A CH 40982A CH 652145 A5 CH652145 A5 CH 652145A5
Authority
CH
Switzerland
Prior art keywords
human
cells
hybrid
cell
mouse
Prior art date
Application number
CH409/82A
Other languages
German (de)
English (en)
Inventor
Gunnar Lars Dr Oestberg
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Priority to CH409/82A priority Critical patent/CH652145A5/de
Priority to DE19833301249 priority patent/DE3301249A1/de
Priority to GB08301384A priority patent/GB2113715B/en
Priority to SE8300290A priority patent/SE502344C2/sv
Priority to FI830190A priority patent/FI83538C/fi
Priority to DK23183A priority patent/DK23183A/da
Priority to FR8300850A priority patent/FR2522679B1/fr
Priority to US06/459,731 priority patent/US4634664A/en
Priority to IL67721A priority patent/IL67721A/xx
Priority to JP58009241A priority patent/JPS58128323A/ja
Priority to AT0019583A priority patent/AT388932B/de
Priority to IT19234/83A priority patent/IT1160468B/it
Publication of CH652145A5 publication Critical patent/CH652145A5/de
Priority to MY169/87A priority patent/MY8700169A/xx
Priority to SG281/89A priority patent/SG28189G/en
Priority to KE3884A priority patent/KE3884A/xx
Priority to HK525/89A priority patent/HK52589A/xx
Priority to CY1488A priority patent/CY1488A/en
Priority to JP2267500A priority patent/JPH03236794A/ja
Priority to JP3157731A priority patent/JPH0789909B2/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/166—Animal cells resulting from interspecies fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CH409/82A 1982-01-22 1982-01-22 Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. CH652145A5 (de)

Priority Applications (19)

Application Number Priority Date Filing Date Title
CH409/82A CH652145A5 (de) 1982-01-22 1982-01-22 Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
DE19833301249 DE3301249A1 (de) 1982-01-22 1983-01-15 Verfahren zur herstellung von humanen monoklonen antikoerpern
GB08301384A GB2113715B (en) 1982-01-22 1983-01-19 Process for the production of human mono-clonal antibodies
SE8300290A SE502344C2 (sv) 1982-01-22 1983-01-20 Hybridomcellinje med förmåga att producera monoklonala antikroppar jämte sätt att framställa cellinjen
FI830190A FI83538C (fi) 1982-01-22 1983-01-20 Foerfarande foer produktion av en hybridomcellinje.
DK23183A DK23183A (da) 1982-01-22 1983-01-20 Fremgangsmaade til fremstilling af humane monoclonale antistoffer
FR8300850A FR2522679B1 (fr) 1982-01-22 1983-01-20 Procede pour la production d'anticorps monoclonaux humains
US06/459,731 US4634664A (en) 1982-01-22 1983-01-20 Process for the production of human mono-clonal antibodies
IL67721A IL67721A (en) 1982-01-22 1983-01-20 Hybridoma cell lines,their preparation and their use for the production of human monoclonal antibodies
JP58009241A JPS58128323A (ja) 1982-01-22 1983-01-21 ヒトモノクロ−ン抗体の製造法
AT0019583A AT388932B (de) 1982-01-22 1983-01-21 Hybridomazellinie und verfahren zu deren herstellung
IT19234/83A IT1160468B (it) 1982-01-22 1983-01-21 Procedimento per la produzione di anticorpi monoclonali umani
MY169/87A MY8700169A (en) 1982-01-22 1987-12-30 Process for the production of human mono-clonal antibodies
SG281/89A SG28189G (en) 1982-01-22 1989-04-27 Process for the production of human mono-clonal antibodies
KE3884A KE3884A (en) 1982-01-22 1989-05-16 Process for the production of human mono-clonal antibodies
HK525/89A HK52589A (en) 1982-01-22 1989-06-29 Process for the production of human mono-clonal antibodies
CY1488A CY1488A (en) 1982-01-22 1989-12-08 Process for the production of human mono-clonal antibodies
JP2267500A JPH03236794A (ja) 1982-01-22 1990-10-03 ヒトモノクローン抗体の製造法
JP3157731A JPH0789909B2 (ja) 1982-01-22 1991-05-30 ハイブリドーマセルラインの製造法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH409/82A CH652145A5 (de) 1982-01-22 1982-01-22 Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.

Publications (1)

Publication Number Publication Date
CH652145A5 true CH652145A5 (de) 1985-10-31

Family

ID=4186382

Family Applications (1)

Application Number Title Priority Date Filing Date
CH409/82A CH652145A5 (de) 1982-01-22 1982-01-22 Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.

Country Status (17)

Country Link
US (1) US4634664A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (3) JPS58128323A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT388932B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH652145A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1488A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3301249A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK23183A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI83538C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2522679B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2113715B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK52589A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL67721A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1160468B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KE (1) KE3884A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8700169A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE502344C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG28189G (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247538A (en) * 1982-05-21 1988-12-28 Mark C. Glassy Human-human hybridomas for solid tumors
US4613576A (en) * 1983-03-09 1986-09-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cancer cells
US4634666A (en) * 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
EP0148644A3 (en) * 1984-01-06 1987-06-03 The Board Of Trustees Of The Leland Stanford Junior University A novel fusion partner and its products
US4764465A (en) * 1984-04-26 1988-08-16 Cetus Corporation Human monoclonal antibody against group A red blood cells
DE3581400D1 (de) * 1984-09-28 1991-02-21 Teijin Ltd Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper.
JPS6187630A (ja) * 1984-10-08 1986-05-06 Teijin Ltd 単純ヘルペスウイルスに対するヒトモノクロ−ナル抗体及びその製造法
US4693975A (en) * 1984-11-20 1987-09-15 The Wistar Institute Human hybridroma fusion partner for production of human monoclonal antibodies
JPS61155398A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤
US4677070A (en) * 1985-04-26 1987-06-30 Cetus Corporation Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use
USH1198H (en) 1985-04-26 1993-06-01 Cetus Corporation Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use
CH670098B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1985-05-23 1989-05-12
JPH0720885B2 (ja) * 1985-09-27 1995-03-08 帝人株式会社 単純ヘルペスウイルス感染症の予防又は治療剤
NZ218499A (en) * 1985-12-10 1990-04-26 Genetic Systems Corp Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods
AU613310B2 (en) * 1986-04-01 1991-08-01 Genelabs Incorporated Immortalized virus-specific tissue cells
EP0262211A1 (en) * 1986-04-01 1988-04-06 Genelabs, Incorporated Immortalized cells which produce tissue-specific products
US5565354A (en) * 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5646041A (en) * 1987-02-12 1997-07-08 Harfeldt; Elisabeth Monoclonal antibody to herpes simplex virus and cell line producing same
US5001065A (en) * 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH01101896A (ja) * 1987-10-14 1989-04-19 Teijin Ltd カンジダに対するヒト・モノクローナル抗体とその製造法
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
IT1226477B (it) * 1988-07-04 1991-01-16 Genetik Mab S R L Linee cellulari n omas quale un mezzo per immortalare cellule produttrici di sostanze di qualunque specie animale.
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2535455B2 (ja) * 1991-02-07 1996-09-18 帝人株式会社 サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ
AU662752B2 (en) * 1991-07-15 1995-09-14 Wellcome Foundation Limited, The Production of antibodies
JPH05276984A (ja) * 1991-09-05 1993-10-26 Teijin Ltd カンジダに対するヒト・モノクローナル抗体を産生するハイブリドーマ
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
FI940811L (fi) * 1992-06-26 1994-02-21 Aetsrn Ihmisen monoklonaalisia anti-Rhesus(D) -vasta-aineita ja niitä tuottavat solulinjat
EP0583980A1 (en) * 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
CA2147600A1 (en) * 1992-11-06 1994-05-26 Lars G. Ostberg Production of human monoclonal antibodies active against hepatitis b surface antigen
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses
PT966533E (pt) 1997-02-07 2010-01-26 Univ Ramot Factor neurotrófico iii dependente da actividade (adnf iii)
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1230269A2 (en) * 1999-11-03 2002-08-14 Maxygen, Inc. Antibody diversity generation
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2002085923A2 (en) 2001-04-19 2002-10-31 The Scripps Research Institute In vivo incorporation of unnatural amino acids
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US20030086929A1 (en) * 2001-10-11 2003-05-08 Tso J. Yun Treatment of prostate cancer by inhibitors of ATP synthase
AU2003304411A1 (en) 2002-08-01 2005-03-07 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
DK1633189T3 (en) 2003-05-19 2017-08-21 Prothena Biosciences Ltd TRUNCTED FRAGMENTS OF ALFA SYNUCLEIN IN LEWY BODY DISEASE
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005018539A2 (en) 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
MXPA05013833A (es) 2003-06-18 2006-05-17 Scripps Research Inst Adiciones al codigo genetico de aminoacidos reactivos no naturales.
EP2465927B1 (en) 2004-05-25 2014-12-24 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
US7973134B2 (en) * 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US7935790B2 (en) * 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
US7807789B2 (en) * 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CN101146554B (zh) 2005-01-27 2012-10-10 加州大学评议会 中和肉毒杆菌神经毒素的治疗性单克隆抗体
BRPI0607374B8 (pt) 2005-01-27 2021-05-25 Childrens Hospital & Res Center At Oakland vacinas de vesículas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
EP2471552B1 (en) 2005-03-08 2015-05-06 MedImmune, LLC Reassortant influenza viruses
US20090099340A1 (en) * 2007-10-12 2009-04-16 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
JP5645361B2 (ja) * 2005-08-02 2014-12-24 エクスバイオテク インコーポレーティッド ＩＬ−１α自己抗体を用いた血管障害の診断、処置、および予防
US20100151495A9 (en) * 2005-08-31 2010-06-17 Cell Signaling Technolgy, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1934867A2 (en) * 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DE602007007071D1 (de) * 2006-04-13 2010-07-22 Medical & Biol Lab Co Ltd Fusionspartnerzellen
US20090298093A1 (en) * 2006-04-27 2009-12-03 Roberto Polakiewicz Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways
US20110008282A1 (en) * 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
AU2007252990B2 (en) * 2006-05-22 2011-10-27 Xbiotech Inc. Treatment of cancer with anti-IL-1alpha antibodies
WO2008011081A2 (en) 2006-07-19 2008-01-24 The Trustees Of The University Of Pennsylvania Wsx-1/p28 as a target for anti-inflammatory responses
US7939636B2 (en) * 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
US20090258442A1 (en) * 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
WO2008083169A2 (en) * 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
US7989173B2 (en) * 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US20090142342A1 (en) * 2006-12-27 2009-06-04 Johns Hopkins University B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases
EP2586458B1 (en) * 2006-12-27 2016-08-24 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
ES2570182T3 (es) 2007-02-23 2016-05-17 Prothena Biosciences Ltd Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica
EP1972639A3 (en) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1975184A3 (en) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serine or threonine phosphorylation sites
US20080238709A1 (en) * 2007-03-28 2008-10-02 Faramarz Vaziri One-way communication apparatus with dynamic key generation
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP1983003A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
EP1983002A3 (en) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosine phosphorylation sites and antibodies specific for them
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
WO2009020923A1 (en) 2007-08-03 2009-02-12 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
ES2628395T3 (es) 2007-08-15 2017-08-02 Bayer Pharma Aktiengesellschaft Anticuerpo regulado por proteasa
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
DK2535428T3 (en) 2007-10-01 2015-11-23 Longhorn Vaccines & Diagnostics Llc Biological prøvesamlings- and transport system, and methods of using
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2195654A1 (en) 2007-10-05 2010-06-16 National Institute for Bioprocessing Research and Training Limited Glycosylation markers for pancreatitis, sepsis and pancreatic cancer
EP2062920A3 (en) 2007-11-21 2009-06-17 Peter Hornbeck Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
US20090169549A1 (en) * 2007-12-19 2009-07-02 The Board Of Regents Of The University Of Texas System Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use
US20090220991A1 (en) * 2008-02-29 2009-09-03 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
EP3023502A1 (en) 2008-04-10 2016-05-25 Cell Signaling Technology, Inc. Compositions and methods for detecting egfr mutations in cancer
SI2285409T1 (sl) 2008-05-30 2016-10-28 Xbiotech, Inc. Protitelesa il-1 alfa
WO2009148150A1 (ja) * 2008-06-06 2009-12-10 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
AU2009268576B2 (en) 2008-07-11 2014-03-27 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
US8242074B2 (en) * 2008-09-12 2012-08-14 Xbiotech, Inc. Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
WO2010093537A2 (en) 2009-02-12 2010-08-19 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
EP2473521A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
KR20130108305A (ko) 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
LT2648752T (lt) 2010-12-06 2017-04-10 Seattle Genetics, Inc. Humanizuoti antikūnai prieš liv-1 ir jų panaudojimas vėžio gydymui
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6062918B2 (ja) 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療
US9809649B2 (en) 2011-09-23 2017-11-07 Xbiotech, Inc. Cachexia treatment
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR102296017B1 (ko) 2012-10-04 2021-09-01 얀센 바이오테크 인코포레이티드 혈관 질환 및 이에 따른 합병증 치료
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
JP6450381B2 (ja) 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
WO2015136469A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3116907A1 (en) 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
EP3288976B1 (en) 2015-04-29 2020-04-08 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva
WO2016183292A1 (en) 2015-05-14 2016-11-17 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA2998716A1 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
BR112018013407A2 (pt) 2015-12-30 2018-12-18 Kodiak Sciences Inc anticorpos e conjugados dos mesmos
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
KR102533675B1 (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
SG11201808434WA (en) 2016-05-02 2018-10-30 Prothena Biosciences Ltd Antibodies recognizing tau
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3482210B1 (en) 2016-07-06 2021-06-23 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
EP3582813A4 (en) 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
US11584790B2 (en) 2017-04-14 2023-02-21 Kodiak Sciences Inc. Complement factor D antagonist antibodies and conjugates thereof
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
US11655307B2 (en) 2017-05-30 2023-05-23 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
BR112020001255A2 (pt) 2017-07-21 2020-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services composições imunogênicas de neisseria meningitidis
JP7292569B2 (ja) 2017-10-06 2023-06-19 ノボ ノルディスク エー／エス トランスサイレチンを検出する方法
WO2019086331A2 (en) 2017-11-02 2019-05-09 Bayer Aktiengesellschaft Bispecific antibodies binding alk-1 and bmpr-2
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
US20220023348A1 (en) 2018-11-28 2022-01-27 Forty Seven, Inc. Genetically modified hspcs resistant to ablation regime
TW202045206A (zh) 2019-02-27 2020-12-16 美商健生生物科技公司 抗體調配物
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US12344665B2 (en) 2020-01-08 2025-07-01 Regeneron Pharmaceuticals, Inc. Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
WO2021211924A1 (en) 2020-04-16 2021-10-21 Janssen Biotech, Inc. Treatment of atopic dermatitis
TW202210514A (zh) 2020-06-02 2022-03-16 美商阿克思生物科學有限公司 針對tigit的抗體
WO2021263279A1 (en) 2020-06-24 2021-12-30 Prothena Biosciences Limited Antibodies recognizing sortilin
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원
CN116745323A (zh) 2021-01-22 2023-09-12 拜耳股份有限公司 Lrrc15抗体及其缀合物
WO2022265912A1 (en) 2021-06-16 2022-12-22 Gundersen Lutheran Medical Foundation, Inc. Antibodies targeting an amphiregulin-derived cell surface neo-epitope
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
EP4527851A1 (en) 2023-09-22 2025-03-26 Bayer Aktiengesellschaft Bispecific antibodies binding ltbr and lrrc15

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757169A1 (de) * 1977-12-22 1979-07-05 Hoechst Ag Verfahren zur gewinnung insulin produzierender tierischer zellen
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
GB2079313A (en) * 1980-07-07 1982-01-20 Nat Res Dev Improvements in or relating to rat myeloma cell lines
DE3167442D1 (en) * 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
JPS57502090A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1980-07-18 1982-11-25
JPS586475B2 (ja) * 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法
JPS5743696A (en) * 1980-08-27 1982-03-11 Hayashibara Biochem Lab Inc Preparation of human luteinizing hormone
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4529694A (en) * 1982-04-16 1985-07-16 The Children's Medical Center Corporation Cell fusion

Also Published As

Publication number Publication date
DE3301249A1 (de) 1983-09-22
JPH0690753A (ja) 1994-04-05
SG28189G (en) 1989-08-11
SE8300290L (sv) 1983-07-23
SE502344C2 (sv) 1995-10-09
GB2113715B (en) 1986-06-04
MY8700169A (en) 1987-12-31
DE3301249C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1990-04-05
JPH0365148B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-10-09
FR2522679A1 (fr) 1983-09-09
FI830190A0 (fi) 1983-01-20
FI830190L (fi) 1983-07-23
IT1160468B (it) 1987-03-11
HK52589A (en) 1989-07-07
JPH0471520B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-11-13
AT388932B (de) 1989-09-25
IL67721A (en) 1986-04-29
FI83538B (fi) 1991-04-15
DK23183D0 (da) 1983-01-20
KE3884A (en) 1989-08-11
JPH03236794A (ja) 1991-10-22
IL67721A0 (en) 1983-05-15
FR2522679B1 (fr) 1986-05-09
GB8301384D0 (en) 1983-02-23
JPH0789909B2 (ja) 1995-10-04
JPS58128323A (ja) 1983-07-30
ATA19583A (de) 1989-02-15
US4634664A (en) 1987-01-06
DK23183A (da) 1983-07-23
CY1488A (en) 1989-12-08
SE8300290D0 (sv) 1983-01-20
GB2113715A (en) 1983-08-10
FI83538C (fi) 1991-07-25
IT8319234A0 (it) 1983-01-21

Similar Documents

Publication Publication Date Title
CH652145A5 (de) Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
EP0260610B1 (de) Monoklonale Antikörper gegen humanen Tumonekrosefaktor (TNF) und deren Verwendung
DE69029015T2 (de) Antikörper gegen menschlichen Interleukin-6-Rezeptor
EP0980390A2 (de) Human-cd28 spezifische monoklonale antikörper zur antigenunspezifischen aktivierung von t-lymphozyten
EP0093436B1 (de) Verfahren zur Herstellung permanenter tierischer und humaner Zellinien und deren Verwendung
EP0499176B1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
DE3249567C2 (de) Hybridzell-Linie, Verfahren zu ihrer Herstellung und ihre Verwendung
CH683526A5 (de) Zellinie für die Herstellung von Antikörper bildenden Hybridomen, Verfahren zur Herstellung einer menschlichen Zellinie und Antikörper produzierendes Hybridom.
DE3786673T2 (de) Verfahren zur entfernung unerwünschter zellen aus menschlichen lymphozytenpopulationen, anwendung des verfahrens zur herstellung monoklonaler antikörper und dafür geeigneter kit.
DE3810331A1 (de) Monoklonale vac-antikoerper
AT396936B (de) Hybridoma zell-linien und verfahren zu ihrer herstellung sowie die verwendung der genannten zell-linien zur herstellung von monoklonalen antikörpern
EP0529348A1 (de) Verfahren zur Reinigung von Faktor XIII, monoklonale Antikörper gegen Faktor XIIIA, ihre Herstellung und Verwendung
CH668775A5 (en) Highly stable hybridomaoma cell line for antibody prodn. - made by fusing secreting cell with compatible xenogeneic hybrid as immortalising component
DE69223337T2 (de) Wachstumsstimulierung durch antiidiotypische Antikörper erzeugt gegen einen für Schweinewachstumshormon spezifischen Antikörper
WO1991009873A1 (de) T-zellen-oberflächenproteine
CH670099A5 (en) New hybridoma cell lines - obtd. by fusing mouse-human hybrid cells with human cells
WO1992004463A1 (de) Cd58 spezifischer monoklonaler antikörper und dessen verwendung
DD250333B1 (de) Verfahren zur herstellung monoklonaler anti-human-t-lymphozytenrezeptor-antikoerper
DD259139B1 (de) Verfahren zur herstellung von monoklonalen antikoerpern gegen common acute lymphoblastic leukemia-associated antigen
DD292021B5 (de) Verfahren zur Herstellung humaner monoklonaler Antikoerper gegen Alpha-Haemolysin von Staphylococcus aureus
DD292021A5 (de) Verfahren zur Herstellung humaner monoklonaler Antikörper gegenAlpha-Hämolysin von Staphylococcus aureus
DE3928861A1 (de) Monoklonale antikoerper gegen humanes neutrophilen-aktivierendes peptid nap/interleukin 8, verfahren zu ihrer produktion, ihre anwendung
DD230879A1 (de) Verfahren zur herstellung monoklonaler antikoerper fuer human-igm
DD274446B5 (de) Verfahren zur herstellung der parentalzellinie cb-fu2
DD230882B1 (de) Verfahren zur herstellung monoklonaler antikoerper fuer ein monozyten-antigen

Legal Events

Date Code Title Description
PFA Name/firm changed

Owner name: SANDOZ AG TRANSFER- NOVARTIS AG

PL Patent ceased